MARKET

RVNC

RVNC

Revance Therapeu
NASDAQ
7.37
+0.28
+3.95%
After Hours: 7.34 -0.03 -0.41% 18:39 12/08 EST
OPEN
7.04
PREV CLOSE
7.09
HIGH
7.54
LOW
6.94
VOLUME
1.23M
TURNOVER
0
52 WEEK HIGH
37.98
52 WEEK LOW
5.72
MARKET CAP
647.19M
P/E (TTM)
-1.4766
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at RVNC last week (1127-1201)?
Weekly Report · 5d ago
Revance Therapeutics: Not Even Daxxify Can Treat Investor Frown Lines
Revance therapeutics' share price has plummeted due to delays in fda approval, legal challenges from abbvie, and disappointing sales of daxxify. The company's focus is on maximising the potential of its approved drug to treat frown lines. Revance faces a make-or-break year - its share price is close to an all-time low.
Seeking Alpha · 11/29 17:06
Weekly Report: what happened at RVNC last week (1120-1124)?
Weekly Report · 11/27 10:57
What 10 Analyst Ratings Have To Say About Revance Therapeutics
Revance therapeutics has an average price target of $29.8 with a high of $44.00 and a low of $12.00. According to 10 analyst offering 12-month price targets in the last 3 months, revance therapeutics has a positive analyst rating. The greater the number of bullish ratings, the more positive analysts are on the stock.
Benzinga · 11/22 17:00
Mizuho Maintains Buy on Revance Therapeutics, Lowers Price Target to $16
Benzinga · 11/22 16:49
Weekly Report: what happened at RVNC last week (1113-1117)?
Weekly Report · 11/20 10:55
Revance Therapeutics files for mixed shelf
Revance therapeutics files for mixed shelf nov. 14, 2023. Revance filed a prospectus for a mixed-shelf offering without disclosing the amount. The company's stock is down 1% to $3.05. Revances is a subsidiary of revance therapeutics, inc.
Seeking Alpha · 11/14 22:52
Weekly Report: what happened at RVNC last week (1106-1110)?
Weekly Report · 11/13 10:49
More
About RVNC
Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on advanced aesthetic and therapeutic offerings. The Company’s aesthetics portfolio of expertly created products and services, including DAXXIFY (DaxibotulinumtoxinA-lanm) for injection, the RHA Collection of dermal fillers, and OPUL, the first-of-its-kind relational commerce platform for aesthetic practices. The Company’s therapeutics pipeline is focused on muscle movement disorders, including evaluating DAXXIFY in two debilitating conditions, cervical dystonia and upper limb spasticity. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient along with the other excipients. DAXXIFY a commercially approved product, is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

Webull offers Revance Therapeutics Inc stock information, including NASDAQ: RVNC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RVNC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RVNC stock methods without spending real money on the virtual paper trading platform.